Doctor of Podiatric Medicine Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Dennis Chaney

Podiatrist, Foot & Ankle Surgery San Antonio, TX Doctor of Podiatric Medicine

NPI 1427107028 CMS profile 64927

1314 E Sonterra Blvd Ste 302, San Antonio, TX 78258

Open in the dashboard

General payments

$15,547

493 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Dennis Chaney of San Antonio, TX is reported in the CMS Open Payments database as having received $15,547 across 493 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Podiatrist, Foot & Ankle Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,582 114
2024 General $1,538 76
2023 General $2,282 82
2022 General $1,284 63
2021 General $5,283 61
2020 General $714 33
2019 General $1,864 64

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Dennis Chaney
  • Podiatrist, Foot & Ankle Surgery median
  • Middle half of Podiatrist, Foot & Ankle Surgery
  • National median

In program year 2025, general payments to Dennis Chaney were reported at $2,582. Among 6,994 Podiatrist, Foot & Ankle Surgery profiles paid that year, the median was $424 and the middle half received between $139 and $1,306.

Show as a table
Year Dennis Chaney Podiatrist, Foot & Ankle Surgery median Middle half National median
2019 $1,864 $389 $118–$1,406 $163
2020 $714 $191 $62–$691 $114
2021 $5,283 $329 $104–$1,341 $132
2022 $1,284 $419 $125–$1,611 $149
2023 $2,282 $377 $128–$1,164 $160
2024 $1,538 $394 $134–$1,168 $164
2025 $2,582 $424 $139–$1,306 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Kerecis Limited $2,869 16 payments
  2. Stryker Corporation $2,572 68 payments
  3. Treace Medical Concepts, Inc. $1,539 45 payments
  4. Medinc of Texas $1,246 2 payments
  5. Paratek Pharmaceuticals, Inc. $1,215 64 payments
  6. Smith+Nephew, Inc. $1,046 69 payments
  7. Integra LifeSciences Corporation $699 13 payments
  8. Organogenesis Inc. $666 41 payments
  9. Melinta Therapeutics, Inc. $566 30 payments
  10. Horizon Therapeutics plc $380 16 payments
  11. Other $2,750 129 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $11,158 485 payments
  2. Consulting Fee $2,400 1 payment
  3. Education $1,200 1 payment
  4. Travel and Lodging $789 6 payments
Products named General payments · program years 2019–2025
  1. Kerecis Omega3 SurgiClose $2,400 1 payment
  2. Kerecis Omega3 Wound $2,400 1 payment
  3. Kerecis Omega3 Surgibind $2,400 1 payment
  4. Kerecis Omega3 GraftGuide $2,400 1 payment
  5. NUZYRA $1,215 64 payments
  6. Lapiplasty System Y $618 11 payments
  7. CADENCE ANKLE REPLACEMENT SYSTEM $532 8 payments
  8. SALTO TALARIS TOTAL ANKLE PROSTHESIS $532 8 payments
  9. AUGMENT INJECTABLE $466 7 payments
  10. LAPIPLASTY SYSTEM Foot And Ankle $410 23 payments
  11. Other $11,818 497 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

333

Median for Podiatry: 160

Drug cost

$4,199

Median for Podiatry: $2,368

Branded share of claims

13.2%

Median for Podiatry: 12.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ammonium Lactate Generic 71 $1,271
Cefdinir Generic 55 $952
Gabapentin Generic 75 $741
Clotrimazole Generic 16 $305
Doxycycline Hyclate Generic 14 $252
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 15 $248
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 16 $125
Tramadol Hcl Generic 34 $121
Levofloxacin Generic 12 $104
Ssd Silver Sulfadiazine Brand 13 $67

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 14,093 Part D prescribers listed as Podiatry; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 81 billing codes

Paid by Medicare

$592,326

Of which drugs: $391,058

Medicare patients

697

Average age 75

Services billed

3,276

366 women, 331 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 56%
Diabetes 47%
Ischemic heart disease 35%
Chronic kidney disease 34%
Atrial fibrillation 23%
Depression 21%
Osteoporosis 18%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, methylprednisolone acetate, 40 mg J1030 Office 24 28 $101
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 52 79 $62

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
NUZYRA
  • Paratek Pharmaceuticals, Inc. $387
$387 — —
Qutenza
  • Averitas Pharma Inc. $70
$70 — —
Kimyrsa
  • Melinta Therapeutics, Inc. $41
$41 — —
JUBLIA
  • Ortho Dermatologics, a division of Bausch Health US, LLC $32
$32 — —
REGRANEX
  • Smith+Nephew, Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

493 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Podiatrist, Foot & Ankle Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record